Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. by Straaten, H.M. van der et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/33276
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Hanneke M. van der Straaten
Anja van Biezen
Ronald Brand
Anton V.M.B. Schattenberg
Roel M. Egeler
Renée M. Barge
Jan J. Cornelissen
Harry C. Schouten
Gert J. Ossenkoppele
Leo F. Verdonck
on behalf of the Netherlands Stem
Cell Transplant Registry “TYPHON”
Allogeneic stem cell transplantation for patients with
acute myeloid leukemia or myelodysplastic syndrome
who have chromosome 5 and/or 7 abnormalities
In recent years the karyotype of acuteleukemia and myelodysplastic syndrome(MDS) has become the most important
prognostic determinant both for initial
response to induction therapy and for remis-
sion duration and overall survival.1-9 Poor
risk cytogenetics in patients with acute
myeloid leukemia (AML) or MDS are espe-
cially abnormalities of chromosome 5
and/or 7 [excluding MDS type refractory
anemia with del(5q)], quite often accompa-
nied by other chromosome abnormali-
ties.1,6–15 The pathological significance of
chromosome 5 and 7 abnormalities is still
unknown.16 In secondary MDS and AML the
abnormalities of chromosome 5 and 7 are
believed to be induced by prior treatment
with alkylating antineoplastic agents.17 With
conventional intensive chemotherapy the
outcome for patients with MDS who have
chromosome 5 and/or 7 abnormalities is as
poor as that for patients with AML having 5
and/or 7 abnormalities.18,19 Currently, the
only established therapy with curative
potential for these poor-risk patients is allo-
geneic stem cell transplantation (SCT),1,10,12,20,21
although this success is counterbalanced by
a rather high transplant-related mortality as
well as relapse.7,12,22 As data on allogeneic
SCT in myeloid leukemias with chromo-
some 5 and/or 7 abnormalities are limited
and only published among those from
patients with other poor-risk cytogenetic
abnormalities we did a retrospective study
of allogeneic SCT in 65 patients with AML
or MDS who had chromosome 5 and/or 7
abnormalities. All patients were registered
at the Netherlands Stem Cell Transplant
Registry (Typhon).
Design and Methods
Patients
A cohort of 65 patients including 16 chil-
dren and 49 adults with poor-risk AML or
MDS who had chromosome 5 and/or 7
abnormalities and who were treated with
allogeneic SCT at six Dutch centers were
studied. The study period dated from 18
January 1983 until 4 October 2001. Forty-six
patients received transplants from HLA-
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Backgrounds and Objectives. Chromosome 5 and/or 7 abnormalities are cytogenetic findings
indicative of a poor prognosis in patients with acute myeloid leukemia (AML) or myelodysplastic
syndrome (MDS). The only potential cure for such patients is allogeneic stem cell transplantation
(SCT). As data on allogeneic SCT in this context are limited we did a retrospective study of allo-
geneic SCT in patients with AML or MDS who had chromosome 5 and/or 7 abnormalities.  
Design and Methods. This was a retrospective study of 65 patients (16 children, 49 adults) with
AML (n=33) or MDS (n=32) who had chromosome 5 and/or 7 abnormalities and who underwent
allogeneic SCT in six Dutch Centers between 1983 and 2001. Data on all these patients are
recorded in the Netherlands Stem Cell Transplant Registry (Typhon). 
Results. The 3-year overall survival rate among all patients was 25%. Patients below the age of 40
years had significantly fewer relapses (40%) and better survival (38%) than those above the age
of 40 (86% and 8%, respectively). Relapses were less frequent in recipients of unrelated grafts
than in those whose grafts were from HLA-identical siblings (30% versus 69%). The development
of acute graft-versus-host disease (GVHD) grades II-IV was independently associated with signifi-
cantly higher transplant-related mortality (TRM). Patients with either chromosome 5 or chromo-
some 7 abnormalities had a significantly better survival than patients with both chromosome 5
and 7 abnormalities. These patients with poor-risk chromosome 5 and/or 7 abnormalities were
compared with a group of patients with a secondary AML/MDS and normal cytogenetics and were
found to have significantly more relapses and significantly worse survival but a similar TRM.
Interpretation and Conclusions. We conclude that patients with AML or MDS with chromosome 5
and/or 7 abnormalities do rather poorly after allogeneic SCT, mainly because of the very high
relapse rate. Nevertheless, this is the only approach that can cure some of these patients.
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identical sibling donors and 19 patients had HLA-
matched unrelated donors (MUD). The diagnosis of
MDS and AML was established by the centers accord-
ing to the French-American-British (FAB) classification
system. Twenty patients had MDS that was not treat-
ed with chemotherapy before the transplant procedure
and 45 patients received induction chemotherapy for
AML or MDS; 30 of these 45 patients achieved com-
plete remission. Those in whom induction failed had
less than 10% blasts in the bone marrow and none had
blasts in the peripheral blood. Sixteen patients had sec-
ondary AML or MDS that had developed after treat-
ment with chemotherapy for other malignancies. All
patients had chromosome 5 and/or chromosome 7
abnormalities. Patients with del (5q) in the context of
MDS-refractory anemia (5q- syndrome) were excluded.
Table 1 shows the characteristics of the patients, their
disease and transplant.
Preparative regimen and management of 
graft-versus-host disease (GVHD)
The conditioning regimen consisted of total body
irradiation and cyclophosphamide in 38 patients and of
busulfan and cyclophosphamide in 27 patients (12 with
melphalan as well). GVHD prophylaxis consisted of T-
cell depletion together with cyclosporine in 40 patients,
and of T-cell depletion alone in 6 patients. Prophylaxis
of GVHD in recipients of grafts that were not T-cell-
depleted was the combination of cyclosporine and
methotrexate (n=16) or cyclosporine monotherapy
(n=3). Patients with acute GVHD grades II-IV and those
with extensive chronic GVHD were treated with high-
dose corticosteroids, sometimes combined with cyclo-
sporine. All patients received post-transplant prophy-
laxis against infections for at least one year with cotri-
moxazole and acyclovir.
Diagnosis and evaluation of GVHD
Acute GVHD (grades I-IV) and chronic GVHD (limit-
ed or extensive) were diagnosed clinically, confirmed
pathologically by skin or mucosal biopsy and classified
according to standard criteria.23 Chronic GVHD was
defined as GVHD present at day 100 onwards after
transplantation.
Statistical analysis
The time intervals for survival, relapse incidence and
transplant-related mortality were calculated from the
day of stem cell transplantation (SCT) onwards. For the
Kaplan-Meier curves (used in univariate descriptions)
and Cox models (used to estimate hazard ratios) the
relapsed patients were censored for transplant-related
mortality at the time of relapse and vice versa.
Univariate comparison of Kaplan-Meier curves was
performed using the two-tailed log-rank test. The trend
version of the log-rank test was used for ordered cate-
gorical variables. The association of various risk factors
with the outcomes overall survival, relapse incidence
and transplant-related mortality was quantified using
hazard ratios estimated in Cox models. Multivariate
analyses were based on proportional hazard models,
calculated using a stepwise backward approach; predic-
tors were removed when their p-value in the likelihood
ratio-test was greater than 0.10. For the purpose of
comparison with other published data and to obtain
Table 1. Underlying disease and characteristics of 65 patients.
Disease at transplantation
Acute myeloid leukemia 33 (51%)
M0 1 (2%)
M1 5 (8%)
M2 10 (15%)
M4 7 (11%)
M5 6 (9%)
Unclassified 4 (6%)
Myelodysplastic syndrome 32 (49%)
RA 10 (16%)
RAEB 8 (12%)
RAEB-t 8 (12%)
CMMoL 6 (9%)
Secondary origin
Acute myeloid leukemia 8 (12%)
Myelodysplastic syndrome 8 (12%)
Type of transplantation
HLA-identical 46 (71%)
Unrelated 19 (29%)
Median age in years (range) 33 (1-60)
Gender
Male 33 (51%)
Female 32 (49%)
Stem cell source
Marrow 57 (88%)
Peripheral blood 7 (11%)
Cord blood 1 (1%)
T-cell depletion
Yes 46 (71%)
No 19 (29%)
Cytogenetics
Del(5q)/-5 6 (9%)
Del(5q)/-5 + other abnormalities 12 (18%)
Del(7q)/-7 22 (34%)
Del(7q)/-7 + other abnormalities 20 (31%)
Del(5q)/-5 + del(7q)/-7 5 (8%)
Monosomy 43 (66%)
Deletion 19 (29%)
Monosomy + Deletion 3 (5%)
Underlying disease and cytogenetics
Chromosome 5 and 7 abnormalities
Acute myeloid leukemia 32 (49%)
Myelodysplastic syndrome
RA 8 (12%)
RAEB 6 (9%)
RAEB-t 8 (12%)
CMMoL 6 (9%)
Chromosome 5 or 7 abnormalities
Acute myeloid leukemia 1 (2%)
Myelodysplastic syndromes
RA 2 (3%)
RAEB 2 (3%)
RAEB-t - (0%)
CMMoL - (0%)
RA: refractory anemia: RAEB: refractory anemia with excess blasts;
RAEB-t: refractory anemia with excess blasts in transfromation;
cMMoL: chronic myelomonocytic leukemia.
valid (non-biased) estimates for the actual probability of
the competing risks of relapse and death in remission,
estimates for relapse incidence and transplant-related
mortality were made using cumulative incidence esti-
mates. The sum of the cumulative incidences of relapse
and transplant-related mortality is the complement of
the relapse-free survival. Since the hazard ratios of the
various risk factors involved in the analyses can be
validly estimated using the Cox model, all inferences in
univariate and multivariate analyses concerning such
risk factors are performed in the framework of Cox
models. The cumulative incidence approach is not real-
ly needed (nor currently feasible) when estimating the
relative effect of the risk factor multivariately: only
when estimating the height of the survival curve itself
does one have to revert to the cumulative incidence
estimate of that curve. As usual, p values < 0.05 were
considered statistically significant. Calculations were
performed in SPSS version 10. The cumulative inci-
dences were calculated in NCSS version 2001. Variables
tested were age: <40 years (n=40) or ≥40 years (n=25);
year of transplantation: £1995 (n=24) or >1995 (n=41); T-
cell depletion: yes (n=46) or no (n=19); chromosome abnor-
malities: chromosome 7 (n=42), chromosome 5 (n=18),
chromosomes 5 and 7 (n=5); monosomy: yes [(n=46;
chromosome 7 (n=36), chromosome 5 (n=6), chromo-
somes 5 and 7 (n=4)] or no [(n=19; chromosome 7
(n=6), chromosome 5 (n=12), chromosomes 5 and 7
(n=1)]; deletion: yes [(n=22; chromosome 7 (n=6), chro-
mosome 5 (n=13), chromosomes 5 and 7 (n=3)] or no
[(n=43; chromosome 7 (n=36), chromosome 5 (n=5),
chromosomes 5 and 7 (n=2)]; the interval between diagno-
sis and SCT: £6 months (n=33) or >6 months (n=32); the
interval between first complete remission and SCT: £3
months (n=19) or >3 months (n=11); stage of disease at
transplantation: untreated [(n=20; refractory anemia n=9,
refractory anemia with excess blasts n=7, chronic
myelomonocytic leukemia  n=4)], first complete remis-
sion [(n=30; AML n=20, refractory anemia n=1, refrac-
tory anemia with excess blasts n=1, refractory anemia
with excess blasts in transformation n=6, chronic
myelomonocytic leukemia n=1)] or complete remission
not achieved after chemotherapy [(n=15; AML n=13,
refractory anemia with excess blasts in transformation
n=2)], acute GVHD: grades 0-I (n=50) or grades II-IV
(n=15); chronic GVHD: none (n=39) or limited and
extensive (n=13); type of SCT: HLA-identical sibling
(n=46) or unrelated donor (n=19); disease at transplanta-
tion: AML (n=33) or MDS (n=32).
Results
There were no significant differences in relapse inci-
dence, overall survival and transplant-related mortality
between AML and MDS patients, therefore both
groups were combined for the analyses. 
Acute and chronic GVHD
No or only grade I acute GVHD was present in 50
patients (77%) whereas acute GVHD grades II-IV
occurred in 15 patients (23%). Thirteen of 52 evaluable
patients (25%) developed chronic GVHD, which was
limited in eight cases (15%) and extensive in five (10%).
Responses and outcome
At 3 years after SCT the overall survival in all 65
patients was 25% (95% confidence interval [95% CI],
14-37%). The relapse incidence at 3 years was 58%
(95% CI: 42-74%) by the Kaplan Meier method and
40% (95% CI: 30-55%) by cumulative incidence
(Figure 1). The 20-month incidence of transplant-relat-
ed mortality was 44% by Kaplan Meier (95% CI: 29-
60%) and 36% (95% CI: 26-50%) by cumulative inci-
dence (no transplant-related deaths occurred more than
20 months after SCT) (Figure 1). 
Univariate analysis
All percentages are based on Kaplan-Meier curves.
The hazard ratios follow from the Cox model. Patients
under the age of 40 years old had a significantly lower
incidence of relapse and better overall survival. The
relapse incidence at 3 years was 40% in patients <40
years and 86% for patients ≥40 years, which corre-
sponds to a hazard ratio of 3.2 (95% CI: 1.5-6.7;
p=0.002) (Table 2) (Figure 2). The overall survival at 3
years in patients <40 years was 38% whereas for
patients ≥40 years it was 8% with a hazard ratio of 1.8
(95%CI: 1.0-3.3; p=0.04) (Table 2). When patients <40
years were divided into two groups, between 0-20
years (n=16) and between 20-40 years (n=24), it
SCT for AML or MDS with 5 and/or 7 abnormalities 
Figure 1. Cumulative incidence of relapse and transplant-related
mortality (TRM) in a competing risk setting. 
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appeared that both subgroups had a significantly lower
relapse incidence (p=0.006) than had patients ≥40 years.
Although both subgroups also had a better overall sur-
vival, the differences were not significant (p=0.1). The
development of acute GVHD grades II-IV was statisti-
cally significantly associated with higher transplant-
related mortality. The 20-month incidence of trans-
plant-related mortality was 32% among patients with
acute GVHD grades 0-1 and 75% among those who
developed grades II-IV, hazard ratio 2.8 (95%CI: 1.2-
6.4; p=0.01) (Table 2). We also found a lower relapse
incidence in recipients of grafts from unrelated donors
than in recipients of grafts from HLA-identical siblings
(p=0.05). The relapse incidence at 3 years in the group
with unrelated donors was 30%, whereas it was 69%
in the group with HLA-identical sibling donors, hazard
ratio 0.4 (95%CI: 0.1-1.1) (Table 2). Furthermore, we
found that patients who underwent SCT without their
disease having been previously treated with chemo-
therapy fared better than those who had been treated
with remission-induction chemotherapy. The relapse
incidence at 3 years was 36% in untreated patients ver-
sus 66% for those in first complete remission following
treatment, hazard ratio: 3.5 (95%CI: 1.0-11.9), versus
61%, hazard ratio: 3.4 (95%CI: 0.9-13.1) for those in
whom induction treatment had failed (p=0.10) (Table
2). The same held true for overall survival at 3 years:
42% for untreated patients versus 23% for patients in
Table 2. Univariate analysis for outcome at 3 years.
Outcomes Variables HR 95%CI p
Overall survival Age 
< 40 yrs 1.0 1.0-3.3 0.04
≥ 40 yrs 1.8
Stage
Untreated 1.0 0.9
Complete remission 1.1 0.6-2.3
No complete remission 1.2 0.5-2.8
Type of SCT
HLA-identical sibling 1.0
Unrelated donor 0.6 0.3-1.3 0.2
Acute GVHD
Grades 0-I 1.0
Grades II-IV 1.6 0.8-3.1 0.2
Chromosome abnormality
5 1.0 0.03
7 0.7 0.4-1.4
5+7 2.6 0.9-7.4
Relapse incidence Age
< 40 yrs 1.0
≥ 40 yrs 3.2 1.5-6.7 0.002
Stage
Untreated 1.0 0.1
Complete remission 3.5 1.0-11.9
No complete remission 3.4 0.9-13.1
Type of SCT
Identical sibling 1.0
Unrelated donor 0.4 0.1-1.1 0.05
Acute GVHD
Grades 0-I 1.0
Grades II-IV 0.6 0.2-1.9 0.4
Chromosome abnormality
5 1.0 0.08
7 0.5 0.2-1.2
5+7 2.3 0.4-11.2
Transplant-related Age
mortality < 40 yrs 1.0
≥ 40 yrs 1.0 0.4-2.4 1.0
Stage
Untreated 1.0 0.09
Complete remission 0.4 0.1-1.0
No complete remission 0.5 0.2-1.6
Type of SCT
HLA-identical sibling 1.0
Unrelated donor 1.2 0.5-2.9 0.7
Acute GVHD
Grades 0-I 1.0
Grades II-IV 2.8 1.2-6.4 0.01
Chromosome abnormality
5 1.0 0.2
7 1.2 0.4-3.4
5+7 3.5 0.8-15.1
Figure 2. Cumulative incidence of relapse and treatment-related
mortality in a competing-risk model, according to age < 40 years
(n=40) and ≥ 40 years (n=25).
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first complete remission with a hazard ratio of 1.1
(95%%CI: 0.6-2.3) versus 21% with a hazard ratio of
1.2 (95%CI: 0.5-2.8) for those in whom induction failed
(p=0.90) (Table 2). Patients with both chromosome 5
and 7 abnormalities had a significantly poorer overall
survival than did patients with either chromosome 5 or
chromosome 7 abnormalities (p=0.03); no difference
was seen for relapse incidence or transplant-related
mortality. The overall survival at 3 years was 15% in
patients with chromosome 5 abnormalities versus
33%, hazard ratio 0.7 (95%CI: 0.4-1.4) in patients with
chromosome 7 abnormalities versus 0%, hazard ratio
2.6 (95%CI: 0.9-7.4) (already after an overall survival of
6 months) in patients with chromosome 5 and 7 abnor-
malities. Comparisons within the group of chromo-
some abnormalities were not significant because of the
small number of patients with both chromosome 5 and
7 abnormalities (n=5) (Table 2).
No significant differences were seen for the other
variables tested: year of transplantation (£1995 or
>1995), T-cell depletion or not, monosomy (yes or no),
deletion (yes or no), those with or without chronic
GVHD, interval between diagnosis or first complete
remission and SCT (£6 months and >6 months or £3
months and >3 months, respectively). 
Multivariate analysis
In view of the results from the univariate analyses
and the small number of patients the multivariate
analyses for overall survival and relapse incidence were
restricted to the variables found to be significant for
overall survival, relapse incidence and transplant-relat-
ed mortality: age, acute GVHD, stage of disease at
transplantation, chromosome abnormalities and type of
SCT. Age had an independent significant effect on over-
all survival and relapse incidence corresponding with a
hazard ratio of 1.9 (95%CI: 1.0-3.4; p=0.05) (Figure 3)
and 3.5 (95%CI: 1.5-7.8; p=0.003), respectively. Patients
above the age of 40 years did far worse than patients
under the age of 40 (Table 3). The chromosome abnor-
malities also had a significant effect on overall survival.
Patients with both chromosomes 5 and 7 abnormalities
had a worse survival than patients with 5 or 7 abnor-
malities (hazard ratio 3.2; 95%CI: 1.1-9.3; p=0.04)
(Table 3). Finally, patients who developed grades II-IV
acute GVHD had a worse overall survival than patients
who developed grades 0-I (hazard ratio 2.2; 95%CI:1.1-
4.6; p=0.03) (Figure 3). This contrasts with the results of
the univariate analysis in which no difference was
found in overall survival according to acute GVHD sta-
tus (p=0.2) (Table 2). The relapse incidence was lower
in untreated patients than in treated patients, whether
these latter had or had not achieved a first complete
remission (p=0.1) (Table 3).
Comparative analysis 
We compared the results in our AML/MDS patients
with high-risk chromosome 5 and/or 7 abnormalities
with the results in secondary AML/MDS patients with
normal cytogenetics. Data for this normal cytogenetics
group were obtained from the MDS study group of the
EBMT Chronic Leukemia Working Party, March 2001,
and kindly provided by Dr. T de Witte, Nijmegen, the
Netherlands. The group consisted of 238 patients with
secondary AML or MDS (sAML/MDS) with normal
Figure 3. Survival according
to acute GVHD and age
based on a Cox model in
which stage of disease at
transplantation and type of
SCT were removed because
they were multivariately non-
significant.
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Table 3. Multivariate Cox regression analysis for overall survival
and relapse incidence.
Outcomes Variables HR 95%CI p
Overall Survival Age
< 40 yrs 1.0
≥ 40 yrs 1.9 1.0-3.4 0.05
Acute GVHD
Grades 0-I 1.0
Grades II-IV 2.2 1.1-4.6 0.03
Chromosome abnormality
5 1.0 0.04
7 0.8 0.4-1.6
5+7 3.2 1.1-9.3
Relapse Incidence Age
< 40 yrs 1.0
≥ 40 yrs 3.5 1.5-7.8 0.003
Stage
Untreated 1.0 0.1
Complete remission 3.8 0.1-13.4
Not complete remission 2.8 0.7-11.3
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
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cytogenetics. We performed a univariate Cox analysis.
The univariate hazard ratios from Cox models compar-
ing the study population with the control population
were virtually identical to the hazard ratios obtained
after a multivariate correction for age and disease status
at transplant. Hence the univariate comparison is not
affected in any way by the main risk factors of age and
disease status. 
The results showed a significantly better overall sur-
vival in the group with normal cytogenetics (p=0.006).
The 3-year survival was 47% in the group with normal
cytogenetics and 25% in our high-risk chromosome 5/7
AML/MDS population; the Cox model showed a haz-
ard ratio of 1.6 (95%CI:1.1-2.2) (Figure 4). The relapse
incidence also differed significantly between the group
with normal cytogenetics and our high-risk chromo-
some 5/7 abnormalities group. At 3 years the relapse
incidence was 30% in patients with normal cytogenet-
ics, whereas it was 58% in the chromosome 5/7 group,
corresponding to a hazard ratio of 2.5 (95%CI:1.6-4.0;
p<0.001) (Figure 4). Transplant-related mortality did not
differ significantly between the two groups. The trans-
plant-related mortality at 20 months was 44% in our
chromosome 5/7 group and 38% in the group with nor-
mal cytogenetics, corresponding to a hazard ratio of 1.1
(95%CI:0.7-1.7; p=0.75) (Figure 4).
Discussion
Our observation that only 25% of patients with
AML/MDS and chromosome 5 and/or 7 abnormalities
are still alive 3 years after a SCT is concordant with pre-
vious data from small series of such patients.1,12 Age
appeared to be a significant prognostic factor both in
univariate and multivariate analyses. Patients below the
age of 40 years had a significantly lower relapse inci-
dence and better overall survival at 3 years than did
those above the age of 40. Remarkably, transplant-relat-
ed mortality was comparable among younger and older
patients. This might have been caused by the (partial)
T-cell depletion of the grafts used in most of the
patients, which decreases GVHD and transplant-related
mortality in older patients. Nevertheless, the trans-
plant-related mortality rate of 44% is remarkably high,
which might be due to the fact that this rate reflects the
outcome of allogeneic transplants carried out in the
1980s and 1990s. More recent studies show lower
transplant-related mortality rates in high-risk leukemia
patients.24
Patients with chromosome 5 and 7 abnormalities
appeared to have worse overall survival and also a high-
er relapse incidence and transplant-related mortality
than did patients with either chromosome 5 or chromo-
some 7 abnormalities, although the number of patients
for this analysis was limited. We did not find any signif-
icant differences between the group of patients with or
without a deletion or monosomy. Another remarkable
fact was that we did not find a lower relapse incidence
and better survival for patients transplanted in complete
remission compared to patients transplanted while not
in complete remission, although none of these latter
patients had more than 10% blasts in their marrow. In
fact untreated patients had a tendency to better out-
come both in univariate and multivariate analyses. This
might be related to the fact that patients who received
SCT in first complete remission had AML or refractory
anemia with excess blasts in transformation whereas
patients who received SCT for untreated disease gener-
ally had less advanced MDS. 
To our knowledge this report of poor-risk AML/MDS
patients with chromosome 5 and/or 7 abnormalities is
Figure 4. Probability of overall survival, relapse incidence and
transplant-related mortality (TRM) for sAML/MDS patients with
normal cytogenetics (n=238) and high-risk AML/MDS patients
with chromosome 5/7 abnormalities (n=65). 
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one of the first studies analyzing a substantial number
of such patients. The comparison of the results of our
high-risk chromosome 5/7 AML/MDS group with the
results of sAML/MDS patients with normal cytogenet-
ics showed comparable transplant-related mortality in
both groups but a significantly higher relapse incidence
in the former group. We postulate that the poor out-
come in our group of high-risk chromosome 5/7
patients is mainly or almost completely due to the
increased relapse rate. We conclude that patients with
AML and MDS with chromosome 5 and/or 7 abnor-
malities do rather poorly after allogeneic SCT, although
this is the only approach that can cure some of these
patients, especially the younger ones. 
The poor survival of 25% at 3 years is mainly caused
by the very high relapse rate in this group, although
given that many of the patients were transplanted a
decade (or more) ago, the transplant-related mortality
might be expected to be decreased and survival
increased nowadays. The better anti-leukemic effect of
grafts from unrelated donors in these poor-risk patients
underscores the importance of the allogeneic effect of
this approach. In patients older than 40 years conven-
tional SCT should be discouraged; non-myeloablative
SCT might be a better approach. Another therapeutic
option for this group of patients might be new
inhibitors of DNA-methylation with a strong anti-
leukemic effect, such as 5-azacitidine and 5-aza-2’-
deoxycytidine.25,26
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